Sawgrass Asset Management LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 32.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,093 shares of the medical research company's stock after selling 11,850 shares during the quarter. Sawgrass Asset Management LLC's holdings in Amgen were worth $8,085,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in Amgen during the third quarter valued at approximately $25,000. Hershey Financial Advisers LLC bought a new position in Amgen in the 2nd quarter worth $30,000. nVerses Capital LLC purchased a new stake in Amgen in the 2nd quarter worth $31,000. Bbjs Financial Advisors LLC bought a new stake in Amgen during the second quarter valued at about $33,000. Finally, Matrix Trust Co purchased a new position in shares of Amgen in the third quarter valued at about $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
AMGN has been the subject of several research analyst reports. StockNews.com upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. TD Cowen lifted their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Dbs Bank raised shares of Amgen to a "strong-buy" rating in a research note on Monday, September 16th. Truist Financial cut shares of Amgen from a "buy" rating to a "hold" rating and boosted their price target for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Finally, Wells Fargo & Company lowered Amgen from an "overweight" rating to an "equal weight" rating and raised their price objective for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $333.57.
Check Out Our Latest Analysis on Amgen
Amgen Price Performance
AMGN opened at $283.61 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The business has a fifty day moving average of $320.85 and a 200 day moving average of $318.36. Amgen Inc. has a 52-week low of $260.52 and a 52-week high of $346.85. The stock has a market cap of $152.45 billion, a P/E ratio of 36.31, a PEG ratio of 2.69 and a beta of 0.60.
Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to analysts' expectations of $8.50 billion. During the same period in the prior year, the business posted $4.96 earnings per share. The business's revenue for the quarter was up 23.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.17%. Amgen's dividend payout ratio (DPR) is currently 115.24%.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.